Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

Analysts may not have crystal balls, but they’re pretty bullish on Vertex’s 2028 outlook, despite its rocky stock performance ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

Read Our Latest Stock Report on VERX Vertex Stock Down 3.3 % Shares of NASDAQ:VERX opened at $32.88 on Friday. The stock has a market capitalization of $5.13 billion, a P/E ratio of 182.67, a PEG ...

Kameleon007 / Getty Images Form 1040EZ, which is no longer used, was the shortest and most straightforward version of Form 1040. What Was Form 1040EZ: Income Tax Return for Single and Joint Filers ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed for now on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

Google Cloud's Vertex AI Search for Healthcare tool is designed ... In healthcare, nearly 90% of healthcare data are in image form such as X-rays, scans or photos. Multimodal technology can ...

Vertex AI Search for healthcare's new ... where nearly 90% of healthcare data is in image form – such as x-rays, scans, or photos. To give healthcare professionals a comprehensive understanding ...